Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Evaluation of NLRP3 Inflammasome Inhibitory Activity Assay from US Patent US20230399319: "Acylsulfamide Compound and Pharmaceutical Use Therefor"
Assay data:409 Active, 380 Activity ≤ 1 µM, 413 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
hTHP-1 assay from US Patent US11724992: "Compounds and compositions for treating conditions associated with NLRP activity"
Assay data:143 Active, 110 Activity ≤ 1 µM, 176 Tested
THP-1 Cells Pyroptosis Assay from US Patent US11530200: "Compounds"
Assay data:21 Active, 10 Activity ≤ 1 µM, 31 Tested
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human monocyte-derived macrophage assessed as reduction in IL-18 secretion in presence of CHC
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human monocyte-derived macrophage assessed as reduction in IL-18 secretion in presence of ATP
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human monocyte-derived macrophage assessed as reduction in ILbeta secretion in presence of CHC
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human whole blood assessed as reduction in ILbeta secretion in presence of calcium pyrophosphate dihydrate
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human whole blood assessed as reduction in ILbeta secretion in presence of cholesterol crystal
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human whole blood assessed as reduction in ILbeta secretion in presence of monosodium urate
Inhibition of NLRP3 inflammasome activation in LPS and ATP-stimulated mouse whole blood assessed as reduction in IL-1beta release preincubated for 3 hrs followed by ATP stimulation and measured after 1 hr
Inhibition of NLRP3 inflammasome activation in LPS-stimulated human monocyte-derived macrophage assessed as reduction in ILbeta secretion in presence of ATP
Inhibition of NLRP3 inflammasome activation in LPS/nigericin stimulated human THP1-ASC-GFP cells assessed as decrease in ASC speck formation preincubated with LPS for 3 hrs followed by compound addition for 30 mins and further stimulated with nigericin by microscopic analysis
Inhibition of NLRP3 induced IL-1beta release in LPS/nigericin-treated mouse BMDM cells preincubated with LPS for 3 hrs followed by compound addition for 30 mins and further stimulated with nigericin for 90 min
Inhibition of NLRP3 induced caspase 1 activity in LPS/nigericin-treated human THP-1 cells preincubated with LPS for 3 hrs followed by compound addition for 30 mins and further stimulated with nigericin for 90 min
Inhibition of NLRP3 inflammasome activation in LPS and ATP-stimulated human whole blood assessed as reduction in IL-1beta release in plasma preincubated for 3 hrs followed by ATP stimulation and measured after 1 hr
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of NLRP3 inflammasome activation in LPS and nigericin-stimulated human PBMC cells assessed as reduction in IL-1beta release preincubated with LPS for 3 hrs followed by compound addition for 30 mins and further stimulated with nigericin for 1.5 hrs by ELISA analysis
Assay data:24 Active, 13 Activity ≤ 1 µM, 24 Tested
Inhibition of NLRP3 inflammasome activation in LPS/MSU-treated C57BL/6 mouse bone marrow-derived macrophages assessed as reduction in IL-1beta secretion preincubated for 3 hrs with LPS and for 30 mins with compound prior to MSU addition and measured after 30 mins by ELISA
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of NLRP3 inflammasome activation in LPS/MSU-treated C57BL/6 mouse bone marrow-derived macrophages assessed as reduction in activated caspase 1(P20) level in cell lysates preincubated for 3 hrs with LPS and for 30 mins with compound prior to MSU addition and measured after 30 mins by Western blot analysis
Inhibition of NLRP3 inflammasome activation in LPS/MSU-treated C57BL/6 mouse bone marrow-derived macrophages assessed as reduction in activated caspase 1(P20) level in culture supernatants preincubated for 3 hrs with LPS and for 30 mins with compound prior to MSU addition and measured after 30 mins by Western blot analysis
Inhibition of NLRP3 inflammasome activation in LPS/MSU-treated C57BL/6 mouse bone marrow-derived macrophages assessed as reduction in cleaved IL-1 beta level in culture supernatants preincubated for 3 hrs with LPS and for 30 mins with compound prior to MSU addition and measured after 30 mins by Western blot analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on